RadNet Acquires UK's CIMAR to Expand AI-Driven Medical Imaging Across Europe

Why Is RadNet Stock Gaining Tuesday? - RadNet (NASDAQ:RDNT)

RadNet Buys CIMAR To Strengthen AI-Driven Radiology In Europe RadNet Inc. (NASDAQ:RDNT), a leading U.S. provider of diagnostic imaging and digital health solutions, announced Tuesday that it has acquired CIMAR UK, a cloud-native healthcare image management company. The acquisition will integrate CIMAR into DeepHealth, RadNet's digital health subsidiary, enhancing AI-powered informatics, improving data interoperability, and streamlining imaging-based care across global healthcare systems.. The move strengthens RadNet's position in connected medical imaging and expands its digital footprint in the UK and Europe. Also Read: Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support By combining DeepHealth's AI-driven tools with CIMAR's interoperability platform, the company aims to improve diagnostic accuracy and operational efficiency for hospitals and clinicians. Kees Wesdorp, CEO and President of RadNet's Digital Health division, stated that the acquisition addresses the mounting pressure on radiologists who face outdated and disconnected tools. He emphasized that merging CIMAR's technology with DeepHealth's informatics systems will enable faster and more accurate diagnoses, as well as streamline care delivery. CIMAR's UK Market Scale CIMAR's infrastructure currently supports more than half of the National Health Service Trusts and around 80% of the UK's private hospitals. Its vendor-neutral platform facilitates efficient image sharing and coordination across healthcare providers. Integrating this system with DeepHealth's AI applications will enhance connected care for patients throughout the region. Leadership Commentary CIMAR CEO Howard Jenkinson described the merger as a "pivotal moment," emphasizing its potential to deliver more seamless and connected imaging experiences. With DeepHealth's technology and RadNet's financial momentum, the company plans to expand AI-driven screening and diagnostic programs across Europe, advancing its goal of more efficient and accessible image-based care. RadNet Q3 Results And 2025 Outlook RadNet's latest quarterly report showed Q3 sales of $522.9 million, surpassing the $494.4 million estimate, though its adjusted EPS of 20 cents fell slightly short of the 22 cents estimate. The company also raised its fiscal 2025 revenue outlook to $1.985-$2.025 billion, up from the previous guidance of $1.93-$1.99 billion, exceeding analyst expectations of $1.973 billion. The strong performance underscores RadNet's continued expansion in AI and digital health. Price Action: RDNT shares were trading higher by 1.46% to $82.03 at last check Tuesday. Photo by T. Schneider via Shutterstock RDNTRadNet Inc $82.001.42% Overview Market News and Data brought to you by Benzinga APIs

RadNet stock falls after acquiring UK imaging solution provider CIMAR By Investing.com

Investing.com -- RadNet Inc (NASDAQ:RDNT) stock fell 3.2% Tuesday after the diagnostic imaging services provider announced the acquisition of CIMAR UK, a cloud-native healthcare image management solutions company. CIMAR will be integrated into DeepHealth, RadNet's wholly owned subsidiary that specializes in AI-powered health informatics, to advance connected imaging-based care. The financial terms of the acquisition were not disclosed. The acquisition combines CIMAR's cloud-native infrastructure, which enhances data connectivity across UK healthcare systems, with DeepHealth's informatics and population health applications. CIMAR currently provides data connectivity to more than 50% of National Health Service Trusts and 80% of UK private hospital groups. "Imaging and diagnostics sit at the forefront of care, serving as the gateway to treatment and disease management," said Kees Wesdorp, CEO and President of RadNet's Digital Health division, DeepHealth. "By acquiring CIMAR, DeepHealth is taking a powerful step in redefining imaging-based care through a portfolio of solutions that connect clinical and operational intelligence to enable faster, more accurate diagnoses and improve efficiency." The two companies already partner on the NHS England's Lung Cancer Screening Program, where CIMAR provides digital infrastructure connecting DeepHealth's AI lung solution across more than 90% of screening sites. According to UK Government data, this program has helped detect 76% of lung cancers at earlier, more treatable stages compared to just 29% historically. Following the acquisition, DeepHealth aims to expand its digitally enabled care models across the UK and Europe for additional screening and diagnostic programs. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.